|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 12, Num. 2, 1995, pp. 81-82
|
Revista Biotecnologia Aplicada 12(2): 81-82
(1995)
REPORTE CORTO/SHORT REPORT
Presented in the Congress Biotecnologia Habana'94. La Habana,
Cuba, Nov. 28 - Dec. 3, 1994
POLYCLONALS TO PEPTIDES: A SEARCH FOR THE MAGIC BULLET
John Buscombe
Department of Nuclear Medicine, Royal Free Hospital and School
of Medicine Pond Street, London, UK
Code Number: BA95022
File Sizes:
Text: 4K
No associated graphics
INTRODUCTION
It has been the dream of clinicians to be able to direct the
therapy to a specific target organ or disease cell and produce
a specific response. This response may vary from stimulation of
cells in the endocrine system to cell death in cancer cells.
Until the 1970s the only weapons available for this were chemical
based on pharmaceuticals. These tended to have a systemic effect,
for example Mustine kills cancer cells but is only slightly less
toxic to normal cells. The discovery of antibodies and of their
unique property of recognising a specific receptor molecule has
brought with it the hope that it might be possible to deliver a
drug or radioisotope to specific cell type whilst other cells
would remain untouched. Hence the idea of a magic bullet guided
to a specific receptor on a specific cell by the specific binding
sites which will bind only with its expected target.
THE ROLE OF NUCLEAR MEDICINE
Nuclear Medicine has been at the forefront of the clinical
application of biotechnology advances into patient care. Nuclear
Medicine is the study of the use of radioisotopes in the
diagnosis and therapy of disease. It provides unique funciontal
information not available with radiology. If the correct isotope
is used the progress of a labelled substance can be easily
followed non-invasively using a gamma camera. Therefore Nuclear
Medicine is an essential partner in turning the products of
biotechnology into clinically useful substances. The aim of this
report is to review the progress in developing disease specific
agents for diagnosis and therapy from standpoint of the Nuclear
Physician.
POLYCLONAL IgG
The simplest method available which will enable imaging using
antibodies is to take blood from a large number of donors these
can be pooled and the labelled. The result will be a non-specific
agent but one which will localise at the sites of highest
antibody activity. This effectively means site of infection and
inflammation.
Preparations of polyclonal human IgG have been used labelled with
two metallic radioisotopes both of which can produce good images.
The first of these is indium-111 (In-111) which is attached to
the IgG via a diethylenepentaacetic acid (DPTA) linker. Trials
in Europe and the United States have shown that it has a high
sensitivity and specificity in imaging infection especially in
patients with AIDS where a sensitivity of 94% and a specificity
of 91% was obtained.
Further work has used a shorter lived isotope which gives better
technetium-99m (Tc-99m). This was linked to polyclonal IgG using
an iminothioline linker. Unfortunately blood pool activity
remains high throughout the test and it has poor results in
infections in the chest and abdomen. In the pelvis and *(however
where blood pool activity is less results in identifying
infection were similar to those obtained using labelled
leucocytes of gallium-67 citrate. In addition it may also be used
to identify inflammatory arthritis
Copyright 1995 Sociedad Iberolatinoamericana de Biotecnologia
Aplicada a la Salud
|